MARKET

NKTR

NKTR

Nektar Therapeutics
NASDAQ
1.710
-0.040
-2.29%
Opening 11:40 05/23 EDT
OPEN
1.740
PREV CLOSE
1.750
HIGH
1.740
LOW
1.650
VOLUME
468.27K
TURNOVER
0
52 WEEK HIGH
1.928
52 WEEK LOW
0.4126
MARKET CAP
314.00M
P/E (TTM)
-1.8595
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at NKTR last week (0513-0517)?
Weekly Report · 3d ago
Weekly Report: what happened at NKTR last week (0506-0510)?
Weekly Report · 05/13 09:23
Nektar Therapeutics 10-Q Report: Financial Condition and Results of Operations
Press release · 05/11 04:22
Nektar's (NKTR) Q1 Earnings and Revenues Surpass Estimates
NASDAQ · 05/10 15:33
NKTR Stock Earnings: Nektar Therapeutics Meets EPS, Beats Revenue for Q1 2024
Nektar Therapeutics reported results for the first quarter of 2024. The company reported earnings per share of -19 cents and revenue of $21.64 million. This was 41.06% better than the analyst estimate for revenue of -18 cents. Nektar Therapyutics is a biopharmaceutical company.
Investorplace · 05/10 02:53
Nektar Therapeutics GAAP EPS of -$0.19, revenue of $21.6M
Seeking Alpha · 05/09 20:22
Nektar Therapeutics Q1 Loss Drops In Line With Estimates
NASDAQ · 05/09 20:19
NEKTAR THERAPEUTICS Q1 PRODUCT SALES USD 6.034 MILLION
Reuters · 05/09 20:15
More
About NKTR
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its pipeline includes NKTR-255, Rezpegaldesleukin (REZPEG) and NKTR-0165. NKTR-255 is an investigational biologic that is designed to target the interleukin-15 (IL-15) pathway in order to activate the body’s innate and adaptive immunity. Its Rezpegaldesleukin pipeline is an investigational, potential first-in-class T regulatory cell stimulator that addresses this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. Rezpegaldesleukin is being developed as a self-administered injection.

Webull offers Nektar Therapeutics stock information, including NASDAQ: NKTR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NKTR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NKTR stock methods without spending real money on the virtual paper trading platform.